# SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Source: https://onco.cc/trials/nct06009029/  
OnCo record `nct06009029` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of zimberelimab in pancreatic cancer, run by Peking University Third Hospital, not yet recruiting.

## Summary

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) is a phase 2, interventional study registered as NCT06009029 by Peking University Third Hospital, with a registry enrolment figure of 96 participants, started 2023-08 and due to reach its primary completion in 2026-07. Interventions recorded: Stereotactic body radiation(SBRT); Zimberelimab (GLS-010). Conditions listed: Locally Advanced Pancreatic Cancer. Primary outcome: Overall survival (OS). Pancreatic eligibility wording from the registry: "* Locally advanced pancreatic cancer confirmed histologically and defined according to the NCCN Pancreatic Cancer Guidelines v1". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06009029
- Phase: 2
- Setting: A Multicenter, Single-arm, Prospective Study of SBRT Combined With Zimberelimab (GLS-010) in Patients With Locally Advanced Pancreatic Cancer (SPARK-1 Study)
- Sponsor: Peking University Third Hospital
- Enrolled: 96

## Sources

- ClinicalTrials.gov NCT06009029: https://clinicaltrials.gov/study/NCT06009029

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06009029.json